Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus subtilis MB40
- Development stage
- Unknown
- Lead developer
- Kerry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis MB40 is a non-genetically engineered, spore-forming probiotic bacterial strain marketed under the brand name Sporevia. Originally developed by BIO-CAT Microbials and licensed to Kerry Group in 2021, it is derived from the Bacillus subtilis Marburg type strain DSM 10. The strain is characterized by high spore stability and works through multiple mechanisms, including the secretion of the lipopeptide fengycin, which exhibits antimicrobial activity. Clinical studies have demonstrated its efficacy in reducing gastrointestinal symptoms such as bloating, gas, and abdominal discomfort in healthy adults. Furthermore, it has shown significant capability in eliminating over 95% of Staphylococcus aureus colonization in the human gut and enhancing immune responses against Listeria monocytogenes in animal models. It holds FDA GRAS (Generally Recognized as Safe) status for use in various food and beverage applications.
- Brand names
- Sporevia
- Other names
- Bacillus subtilis ATCC PTA-122264Bacillus subtilis strain MB40
02
Targets
agr (Accessory gene regulator system)
Beyond the preview
Go deeper on Bacillus subtilis MB40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus subtilis MB40.